ISEV MRS Joint Meeting Speakers
Share |

 

Keynote Speakers

Muller Fabbri, MD, PhD
University of Hawaii Cancer Center

Muller Fabbri, MD, PhD is currently Associate Professor in the Cancer Biology Program at the University of Hawaii Cancer Center. He received his MD degree at the University of Pisa, Italy in 1997 and earned the graduation degree in Medicine and Surgery of the Sant'Anna School of Specialized Studies in Pisa, Italy. He earned a specialization in Medical Oncology at the University of Ferrara, Italy and subsequently a PhD in Molecular and Cellular Biotechnologies at the Second University of Naples, Italy. In 2003 he joined the Thomas Jefferson University in Philadelphia, PA as a post-doctoral researcher and transferred with the whole lab at the Ohio State University in Columbus, OH in 2004. In 2008 he became Research Scientist with Principal Investigator Status and in 2012 he was appointed Assistant Professor of Pediatrics and Molecular Microbiology & Immunology at Children's Hospital Los Angeles, University of Southern California in Los Angeles, CA, where he stayed until 2018, when he moved to his current position. His research focuses on the role of microRNAs (and other non-coding RNAs) in the biology of cancer and the tumor microenvironment, with a particular interest in the involvement of exosomes and other extracellular vesicles in the progression of cancer and the development of drug resistance. He has authored more than 90 publications and several book chapters. He has edited a volume on "Non-coding RNAs and Cancer" and is frequently invited to give seminars and lectures in national and international venues. He has contributed some of the most seminal discoveries on the role of microRNAs as regulators of the epigenetic machinery and provided the first evidence that microRNAs can function as agonists of cellular receptors

 
Jennifer Jones, MD, PhD,
National Cancer Institute
Center for Cancer Research

Dr. Jones is an Investigator in Laboratory of Pathology at the National Cancer Institute.  Her use of -omics approaches to study complex problems began early in her career as a graduate student and postdoctoral fellow, when she positionally cloned the TIM gene family and demonstrated the genetic association between TIMs and immune response profiles (McIntire et al., Nature Immunology 2001, and Nature 2003). Now as a practicing a radiation oncologist, her long term clinical goals are focused on developing immune-based therapies that synergize with radiation to produce optimal anti-tumor immune responses.  The broader impact of her current work relates to her development of a new approach to precision medicine using EVs as nanoscale packets of information for real-time monitoring of treatment responses.  To make EV analyses relevant for clinical studies, Dr. Jones is developing improved methods to characterize, sort, and perform functional studies of nanoparticles and has established a high throughput EV analysis pipeline and NCI's Translational Nanobiology Lab, with instrumentation for preparation, analysis, counting, and cytometric study of extracellular vesicles.

 

Hakho Lee. PhD
Mass General Hospital
Harvard Medical School

Dr. Lee is Associate Professor in Radiology at Harvard Medical School, Director of the Biomedical Engineering Program at the Center for Systems Biology, Massachusetts General Hospital (MGH), and Hostetter MGH Research Scholar. He received his Ph.D. in Physics from Harvard University and completed his postdoctoral training at MGH. Dr. Lee has extensive experience in nanomaterials, biophysics, microfluidics, and electrical engineering. His research focuses on developing novel biomedical sensors for clinical applications, for example, the world’s smallest portable NMR device, integrated circuit (IC) chips for cancer cell detection, and a point-of-use device for allergen detection. Many of these systems have been translated clinical applications. Dr. Lee’s group also pioneered new analytical technologies for EV characterization, including nPLEX (nanoplasmonic exosome), iMEX (integrated magneto-electrochemical exosome), iMER (integrated magnetic exosomal RNA), and SEA (single EV analyses). 

 

Jan Lötvall, MD, PhD
University of Gothenburg

 Jan Lötvall is Professor at the Institute of Medicine at Göteborg University since 2002 where he directs a research laboratory studying extracellular vesicles. He is a medical specialist in both Clinical Allergy and Clinical Pharmacology and has a long-term experience in translational studies in in primarily inflammatory models, but also cancer. He was first elected President of the International Society of Extracellular Vesicles (ISEV, 2011-2016), a rapidly growing non-profit organisation in the field of exosomes, microvesicles and other extracellular vesicles (www.isev.org; >1000 members 2017). The research line focusing on extracellular vesicle biology has received extensive international recognition, as the lab was first to discover the ability of exosomes to shuttle RNA between cells in 2007. During the period of May 2016 to January 2018, JL served as Chief Scientist at Codiak BioSciences, a startup biotech company focusing on developing exosomes as a therapeutic platform. From January 2018, JL is currently having a sabbatical at Massachusetts General Hospital, working with Professor Xandra Breakefield (Harvard).  Jan has been an editor of the open access journal Respiratory Research (IF 3.85) from April 2003 to August 2018, and was the founding editor of the journals “Clinical and Translational Allergy” (2011, IF 3.239) and Journal of Extracellular Vesicles (unofficial IF >10). 
David Lyden, MD, PhD
Weill Cornell Medical Center


 Dr. Lyden completed his M.D. at Brown University, Ph.D. at the University of Vermont, his residency in Pediatrics at Duke University Medical Center, and a fellowship in Pediatric Hematology/Oncology at Memorial Sloan Kettering Cancer Center. Currently, he is the Stavros S. Professor of Pediatrics and Cell and Developmental Biology at Weill Cornell Medicine.

His early work resulted in several fundamental discoveries that involve the role of bone marrow-derived stem and progenitor cells in tumor vasculogenesis and in metastasis.  He and his colleagues made a pivotal discovery in the metastatic cascade which revealed that tumor-secreted factors induce the formation of microenvironments in distant organs that are conducive to tumor cell survival and outgrowth prior to their arrival at these sites putting forward the concept of the "pre-metastatic niche".  They also found that tumor-secreted microvesicles, known as exosomes, initiate pre-metastatic niche formation through key proteins (i.e., oncoproteins, integrins) and nucleic acids in exosomes that support thrombosis generation and vascular leakiness. In addition, his team discovered double-stranded DNA by enzymatic methods and structural studies in tumor exosomes. Thus, exosomal molecules may serve as valuable biomarkers for detection of oncogenesis and metastatic progression. His work has engendered a new appreciation for how primary tumor cells dictate their own metastases by decoding how cancer-derived exosomes mediate intercellular communication. Most recently, Dr. Lyden has identified specific exosome subpopulations and discovered new subset of particles known as exomeres which collectively have distinct functional roles in the systemic effects of cancer.  

 

Andy Minn, MD, PhD
University of Pennsylvania

 

Dr. Minn is an Associate Professor in the Department of Radiation Oncology and Abramson Family Cancer Research Institute at the University of Pennsylvania. His laboratory is focused on understanding the role of pattern recognition receptors (PRR) and interferon (IFN) signaling pathways in cancer. These pathways are typically associated with pathogen infection; however, in the context of cancer, endogenous nucleic acids can mimic viral infection. As a consequence, ensuing anti-viral signaling can orchestrate tumor progression, response to conventional therapies, response to immunotherapies, and influence the immune microenvironment. Moreover, these PRR/IFN pathways can be therapeutically exploited to modulate the immune system. One way is through activation of the DNA damage response. An overarching goal is to translate mechanistic findings to better inform the design of clinical trials.

Janusz Rak, MD, PhD
McGill University
Janusz Rak, MD, PhD trained in Poland, United States and Canada and is currently a Professor of Pediatrics, Experimental Medicine and Biochemistry at McGill University in Montreal, Canada. He is also a Principal Investigator at the Research Institute of the McGill University Health Centre and Jack Cole Chair in Pediatric Hematology/Oncology. His research interests in extracellular vesicles concentrate on their role in cancer, particularly as biomarkers and mediators of aberrant intercellular communication and vascular pathologies, such as angiogenesis and thrombosis. His laboratory investigates how extracellular vesicles and other mediators contribute to the onset, progression and dissemination of brain tumours and other malignancies, including in children, and under the influence of disease-causing genetic and epigenetic oncogenic triggers.  Dr. Rak published over 150 scientific papers and is currently supported by grants from Canadian Institutes of Health Research, Canadian Cancer Society Research Institute and other agencies. 
Clotilde Théry, PhD
Institut Curie
 Dr. Clotilde Théry is an INSERM director of research (DR2) working at Institut Curie, where she heads a team created in 2007 within the "Immunity and Cancer" INSERM Unit U932, entitled "Extracellular Vesicles, Immune responses and Cancer". Since 1998, her scientific interests have focused on the study of exosomes (and more recently extracellular vesicles in general), secreted by immune and tumor cells, and their roles in communications between tumors and the immune system. Her goals are to understand the physiological functions of EV secretion during an in vivo immune response and during tumor growth, and her approach is to continuously go from basic cell biology questions on their modes of formation to application of this knowledge to in vivo situations.

C. Théry is regularly invited to write reviews on the subject of exosomes, EVs, their immune functions and their biogenesis. She has organized several symposia and sessions dedicated to exosomes in international meetings, and in particular a first “International Workshop on Exosomes” in Institut Curie, in Paris, in 2011, which ledto the creation of the International Society for Extracellular Vesicles (ISEV). 

 

The International Society For Extracellular Vesicles (ISEV) is a professional society of researchers and scientists of exosomes and microvesicles.

Our Mission: Advancing extracellular vesicle research globally.

Contact Us

International Society for Extracellular Vesicles
19 Mantua Road
Mount Royal, New Jersey 08061
USA

Phone: 856-423-1621
Email: contact@isev.org

Connect With Us
Become A Member